Celgene $CELG and Agios Pharmaceuticals $AGIO signed a partnership deal with Abbott $ABT to develop and commercialize companion diagnostic tests to identify isocitrate dehydrogenase (IDH) mutations in patients with acute myeloid leukemia (AML). The tests will be conducted on Abbott�s m2000 RealTime System, an automated polymerase chain reaction (PCR) instrument. Celgene is focusing on the development of IDH2 inhibitor, enasidenib, for the treatment of IDH2-positive AML. Agios is developing an IDH1 inhibitor, AG-120 for AML patients positive for that mutation.
finviz dynamic chart for  CELG